Ombitasvir is a direct acting antiviral agent used in combination with other antiviral agents for the treatment of Hepatitis C Virus (HCV) infections. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed · 1 reference
Ombitasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly. Potential modes of action of NS5A inhibitors like Elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex.
- Primary indication
- When used in combination with DB09297 and DB00503 (as the fixed dose product Technivie), Ombitasvir is indicated in combination with DB00811 for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection...Curator reviewed · 3 structured indications
- Formula / weight
- C50H67N7O8 · 894.127 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2014
- Code names
- ABT-267
- Brand names
Resolves to
PIDFDZJZLOTZTM-KHVQSSSXSA-NSMILESCOC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1What you can answer from here — as of August 29, 2026
Which drugs share a target with Ombitasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account